The Gap Between Global Tuberculosis Incidence and the First Milestone of the WHO End Tuberculosis Strategy: An Analysis Based on the Global Burden of Disease 2017 Database
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The first milestone (in 2020) of the End Tuberculosis (TB) Strategy of the World Health Organization was a 20% reduction in TB incidence rate compared with the 2015 baseline. This study aimed to determine the incidence rate of TB and how it has changed since 2015 at the global, regional, and country levels. METHODS: This study used the most recent data from the Global Burden of Disease study in 2017 to extract TB incidence rates at the global, regional, and country levels. The annual percentage change in the incidence rate (APCIR) of TB based on 2015 was calculated to evaluate the trend in the changes at various levels, including globally and at the regional and country levels. An APCIR of -4% from 2015 to 2020 is considered acceptable. RESULTS: The global APCIR was only -1.1% from 2015 to 2017. Only 2 of the 21 analyzed regions had APCIRs lower than -4%: Southern Sub-Saharan Africa and Eastern Europe. Worse still, six regions exhibited increasing TB incidence rates. At the country level, although 143 of 195 countries and territories showed reductions in TB incidence rates, the APCIR was lower than -4% in only 11 of them. CONCLUSION: This study suggests that it will be difficult to achieve the 2020 incidence rate milestone of the End Tuberculosis Strategy. This indicates the need to design and implement suitable strategies to address the current situation in order to achieve the next milestone and targets of the End Tuberculosis Strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent progress has been unimpressive, however, as global annual rates of decline in tuberculosis incidence over the past 10 years have ranged between 1% and 2%.3, 4”
From Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021 (2024) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Roth, G. A., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32203-7 · Cited by 8,600
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07492-2 · Cited by 7,007
Naghavi, M., Abajobir, A. A., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abera, S. F., Aboyans, V., Adetokunboh, O., Afshin, A., Agrawal, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32152-9 · Cited by 4,821
Uplekar, M., Weil, D., Lonnroth, K., Jaramillo, E., Lienhardt, C., Dias, H. M., Falzon, D., Floyd, K., Gargioni, G., Getahun, H., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60570-0 · Cited by 1,117
Floyd, K., Glaziou, P., Zumla, A., & Raviglione, M. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30057-2 · Cited by 440
Kyu, H. H., Maddison, E. R., Henry, N. J., Ledesma, J. R., Wiens, K. E., Reiner, R., Biehl, M. H., Shields, C., Osgood-Zimmerman, A., Ross, J. M., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30625-x · Cited by 437
The global burden of tuberculosis: results from the Global Burden of Disease Study 2015
Kyu, H. H., Maddison, E. R., Henry, N. J., Mumford, J. E., Barber, R., Shields, C., Brown, J. C., Nguyen, G., Carter, A., Wolock, T. M., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30703-x · Cited by 376
What We Know About Tuberculosis Transmission: An Overview
Churchyard, G., Kim, P., Shah, N. S., Rustomjee, R., Gandhi, N., Mathema, B., Dowdy, D., Kasmar, A., & Cardenas, V. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix362 · Cited by 341
The WHO's new End TB Strategy in the post-2015 era of the Sustainable Development Goals
Lönnroth, K., & Raviglione, M. (2016) · Transactions of The Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/trv108 · Cited by 200
Measuring global health: motivation and evolution of the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32367-x · Cited by 191
Tuberculosis origin: The Neolithic scenario
Hershkovitz, I., Donoghue, H. D., Minnikin, D. E., May, H., Lee, O. Y.-C., Feldman, M., Galili, E., Spigelman, M., Rothschild, B. M., & Bar‐Gal, G. K. (2015) · Tuberculosis · doi:10.1016/j.tube.2015.02.021 · Cited by 174
The current status, challenges, and future developments of new tuberculosis vaccines
Gong, W., Liang, Y., & Wu, X. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1458806 · Cited by 144
Tuberculosis disease burden and attributable risk factors in Nigeria, 1990–2016
Ogbo, F. A., Ogeleka, P., Okoro, A., Olusanya, B. O., Olusanya, J. O., Ifegwu, I. K., Awosemo, A. O., Eastwood, J. G., & Page, A. (2018) · Tropical Medicine and Health · doi:10.1186/s41182-018-0114-9 · Cited by 111
Tichenor, M., & Sridhar, D. (2019) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15011.1 · Cited by 99
Tuberculosis in a rural population of South India: a five-year epidemiological study.
(1974) · Europe PMC (PubMed Central) · Cited by 98
Methods used by WHO to estimate the Global burden of TB diseasePreprint
Glaziou, P., Sismanidis, C., Pretorius, C., & Floyd, K. (2016) · arXiv (Cornell University) · doi:10.48550/arxiv.1603.00278 · Cited by 71
End TB strategy: the need to reduce risk inequalities
Gomes, M. G. M., Barreto, M. L., Glaziou, P., Medley, G. F., Rodrigues, L. C., Wallinga, J., & Squire, S. B. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1464-8 · Cited by 22
Gebremichael, B., Abebaw, T.-A., Moges, T., Abaerei, A. A., & Worede, N. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3163-0 · Cited by 15
Tuberculosis: An Epidemic Perpetuated by Health Inequalities.
Szkwarko, D., Bouton, T. C., Rybak, N., Carter, E. J., & Chiang, S. S. (2019) · PubMed · Cited by 4
Research works printed but not linked: 1
- Szkwarko, 2019, Rhode Island Med j, 102, 47
Cited by
Ledesma, J. R., Ma, J., Zhang, M., Basting, A. V. L., Chu, H. T., Vongpradith, A., Novotney, A., LeGrand, K. E., Xu, Y. Y., Dai, X., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00007-0 · Cited by 146
Tuberculosis Treatment Outcome and Predictors in Africa: A Systematic Review and Meta-Analysis
Teferi, M., El‐Khatib, Z., Boltena, M. T., Tarekegn, A., Asamoah, B. O., Biru, M., & Taye, H. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182010678 · Cited by 90
Zou, Z., Liu, G., Hay, S. I., Basu, S., Belgaumi, U. I., Dhali, A., Dhingra, S., Fekadu, G., Golechha, M., Joseph, N., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101646 · Cited by 66
Bu, Q., Qiang, R., Fang, L., Peng, X., Zhang, H., & Cheng, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1156249 · Cited by 49
Self-citationZhang, T., Zhang, J., Wei, L., Liang, H., Zhang, J., Shi, D., & Wang, Z. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.01.014 · Cited by 43
Self-citation
Metadata
- Authors
- Pan, Z., Zhang, J., Bu, Q., He, H., Bai, L., Yang, J., Liu, Q., & Lyu, J.
- Affiliations
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Northwest Women's and Children's Hospital (CN)
- Corresponding author
- Lyu, Jun
- Venue
- Infection and Drug Resistance
- Publisher
- Informa UK Limited
- Published
- 2020-05
- Volume
- Volume 13
- Pages
- 1281-1286
- ISSN
- 1178-6973 (ISSN-L)
- PMC
- PMC7210037
- OpenAlex
- W3022973077
- Cited by
- 29
- References
- 21
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 9 · 2023: 7 · 2022: 7 · 2021: 3 · 2020: 1
- FWCI
- 0.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Infection and Drug Resistance (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- National Social Science Fund of China (16BGL183, No. 16BGL183)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › HIV, TB, and STIs Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- tuberculosis incidence, End TB Strategy, global burden of disease, incidence trends, regional disparities
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.